NASDAQ:GOSS Gossamer Bio Q2 2025 Earnings Results & Report $8.97 -0.79 (-8.10%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more. Gossamer Bio beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 5, 2025. The company reported EPS of -$13.60 versus the -$14.40 consensus estimate, while revenue of $11.49 million topped the $4.12 million estimate by $7.37 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 5, 2025TimeBefore Market OpensConference Call4:00 PM ET Gossamer Bio EPS ResultsActual EPS-$13.60Consensus EPS -$14.40Beat/MissBeat by +$0.80One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersGossamer Bio Revenue ResultsActual Revenue$11.49 millionExpected Revenue$4.12 millionBeat/MissBeat by +$7.37 millionYoY Revenue GrowthN/AUpcoming EarningsGossamer Bio's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Gossamer Bio Q2 2025 Earnings FAQ Did Gossamer Bio beat earnings estimates for Q2 2025? Gossamer Bio (NASDAQ:GOSS) reported earnings of -$13.60 per share for Q2 2025, beating the consensus estimate of -$14.40. The report was announced on Tuesday, August 5, 2025. What was Gossamer Bio's revenue for Q2 2025? Gossamer Bio reported revenue of $11.49 million for Q2 2025, against a consensus estimate of $4.12 million. When is Gossamer Bio's next earnings date? Gossamer Bio's next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Gossamer Bio on the company's earnings history page. Gossamer Bio Earnings HeadlinesChardan Initiates Gossamer Bio at Buy With $160 Price TargetOctober 13 at 9:20 AM | marketscreener.comMGossamer Bio average analyst price target decreased by 40.76% to $80.05October 2, 2026 | msn.comMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market.October 14 at 1:00 AM | Crypto 101 Media (Ad)Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDAOctober 1, 2026 | finance.yahoo.comGossamer Bio Regains Nasdaq Listing Bid Price ComplianceSeptember 30, 2026 | theglobeandmail.comGossamer Bio, Inc. Submits New Drug Application to U.S. Fda for Seralutinib for Treatment of Pulmonary Arterial HypertensionSeptember 24, 2026 | marketscreener.comMSee More Gossamer Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email. Email Address About Gossamer BioGossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations. Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling. The therapy is being evaluated for pulmonary arterial hypertension, a serious and progressive disease affecting the blood vessels of the lungs. Seralutinib has advanced into late-stage clinical development, with the company seeking to establish its safety and efficacy as a potential treatment option. The company has also developed additional programs targeting immune and inflammatory diseases, including investigational therapies directed at kinase and other disease-related pathways. Gossamer Bio was founded in 2015 and became a publicly traded company in 2019. Its research and development activities are focused primarily on the United States, while collaborations with international pharmaceutical companies support the potential development and commercialization of its therapies in global markets. Faheem Hasnain, a co-founder of Gossamer Bio, has served as the company’s chairman and chief executive officer. The company’s strategy centers on advancing internally developed therapies through clinical trials and working with strategic partners to expand the reach of successful treatments.View Gossamer Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
